

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

**Metabolic-activity based assessment of antimicrobial effects  
by D2O-labeled Single-Cell Raman Microspectroscopy**

Journal:	<i>Analytical Chemistry</i>
Manuscript ID	ac-2016-05051v.R1
Manuscript Type:	Article
Date Submitted by the Author:	28-Feb-2017
Complete List of Authors:	Tao, Yifan; Sun Yat-sen University, Department of Operative Dentistry and Endodontics; Chinese Academy of Sciences, Qingdao Institute of BioEnergy and Bioprocess Technology Wang, Yun; Chinese Academy of Sciences, Qingdao Institute of BioEnergy and Bioprocess Technology Huang, Shi; Chinese Academy of Sciences, Qingdao Institute of BioEnergy and Bioprocess Technology Zhu, Pengfei; Chinese Academy of Sciences, Qingdao Institute of BioEnergy and Bioprocess Technology Huang, Wei; University of Oxford, Department of Engineering Science Ling, Jun-Qi; Guanghua School of Stomatology Xu, Jian; Chinese Academy of Sciences, Qingdao Institute of BioEnergy and Bioprocess Technology

SCHOLARONE™  
Manuscripts

# Metabolic-activity based assessment of antimicrobial effects by D<sub>2</sub>O-labeled Single-Cell Raman Microspectroscopy

Yifan Tao<sup>1,2</sup>, Yun Wang<sup>2,4</sup>, Shi Huang<sup>2,4</sup>, Pengfei Zhu<sup>2,4</sup>, Wei E Huang<sup>3</sup>, Junqi Ling<sup>1, \*</sup>, Jian Xu<sup>2,4, \*</sup>

<sup>1</sup>Operative Dentistry and Endodontics, Guanghua School of Stomatology, Affiliated Stomatological Hospital, Guangdong Province Key Laboratory of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, 510055, China

<sup>2</sup>Single-Cell Center, CAS Key Laboratory of Biofuels and Shandong Key Laboratory of Energy Genetics, Qingdao Institute of BioEnergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, Shandong, 266101, China.

<sup>3</sup>Department of Engineering Science, University of Oxford, Parks Road, Oxford, OX1 3PJ, United Kingdom.

<sup>4</sup>University of Chinese Academy of Sciences, Beijing, 100049, China.

\*Corresponding author: Jian Xu and Junqi Ling

[xujian@qibebt.ac.cn](mailto:xujian@qibebt.ac.cn) and [lingjq@mail.sysu.edu.cn](mailto:lingjq@mail.sysu.edu.cn)

Telephone:+86 (0)532-80662651

18 **ABSTRACT**

1  
2  
3 19 To combat the spread of antibiotic resistance, methods that quantitatively assess metabolism-  
4  
5 20 inhibiting effects of drugs in a rapid and culture-independent manner are urgently needed. Here using  
6  
7 21 four oral bacteria as models, we show that heavy water (D<sub>2</sub>O) based Single-cell Raman  
8  
9 22 Microspectroscopy (D<sub>2</sub>O-Raman) can probe bacterial response to different drugs using the Raman shift  
10  
11 23 at C-D (carbon-deuterium vibration) band in 2,040 to 2,300 cm<sup>-1</sup> as a universal biomarker for metabolic  
12  
13 24 activity at single bacterial cell resolution. "Minimum Inhibitory Concentration based on Metabolic  
14  
15 25 Activity" (MIC-MA), defined as the minimal dose under which the median  $\Delta$ C-D-ratio at 8 h of drug  
16  
17 26 exposure is  $\leq 0$  and the Standard Deviation (SD) of the  $\Delta$ C-D ratio among individual cells is  $\leq 0.005$ , was  
18  
19 27 proposed to evaluate the metabolism-inhibiting efficacy of drugs. In addition, Heterogeneity Index of  
20  
21 28 MIC-MA (MIC-MA-HI), defined as SD of C-D ratio among individual cells, quantitatively assesses the  
22  
23 29 among-cell heterogeneity of metabolic activity after drug regimens. When exposed to 1 $\times$  MIC of  
24  
25 30 sodium fluoride (NaF), 1 $\times$  MIC of chlorhexidine (CHX) or 60 $\times$  MIC of ampicillin, the cariogenic oral  
26  
27 31 pathogen *Streptococcus mutans* UA159 ceased propagation yet remained metabolically highly active.  
28  
29 32 This underscores the advantage of MIC-MA over the growth-based MIC in being able to detect the  
30  
31 33 'non-growing but metabolically active' (NGMA) cells that underlie many latent or recurring infections.  
32  
33 34 Moreover, antibiotic susceptible and resistant *S. mutans* strains can be readily discriminated at as early  
34  
35 35 as 0.5 h. Thus D<sub>2</sub>O-Raman can serve as a universal method for rapid and quantitative assessment of  
36  
37 36 antimicrobial effects based on general metabolic activity at single-cell resolution.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 39 Introduction

40 To combat the rapid spread of microbial drug resistance, fast, sensitive and reliable methods for  
41 quantitative assessment of antimicrobial activities are urgently needed<sup>1-2</sup>. Currently such methods can be  
42 broadly classified as 'growth-based' or 'non-growth based'. Growth-based methods typically examine the  
43 sensitivity of cell growth curve to drugs via dilution and diffusion, and quantitative parameters such as  
44 'minimum inhibitory concentration' (MIC) was derived<sup>3</sup>. These methods can be time consuming  
45 (frequently exceeding 24 h for the most common pathogens as extended duration of drug exposure is  
46 required), and moreover are usually not capable of tackling viable but nonculturable microbes<sup>4-5</sup>.  
47 Furthermore, as growth inhibition does not necessarily correlate with metabolic inhibition or cell death,  
48 growth-based methods are usually not capable of distinguishing between bactericidal and bacteriostatic  
49 effects and consequentially fail to detect 'non-growing but metabolically active' (NGMA) cells, which  
50 are responsible for many latent or recurring infections (due to their ability to resume growth after  
51 removal of antimicrobials) and eventually lead to treatment failure<sup>6</sup>.

52 On the other hand, non-growth based approaches measure cellular phenotypes that correlate with  
53 inhibition of cellular metabolism, independent of cell proliferation<sup>7-8</sup>. For example, intracellular ATP  
54 content of a cellular population, which is typically reduced due to drug inhibition of cellular metabolism,  
55 can be assayed via luminescence generated by luciferase-catalyzed luciferin oxygenation that uses ATP  
56 as energy supply<sup>9</sup>. However, despite their value in assessing the drug effect on energy metabolism, such  
57 methods can be misleading when the drug targets other cellular processes or even elevates intracellular  
58 ATP level (e.g., in the case of rifampin, as a response to respiration-deceleration<sup>10</sup>). Moreover, ATP  
59 assays, normally performed at the bulk cell level, measure ensemble-averaged parameters and are  
60 unable to assess the heterogeneity of drug sensitivity or drug response within a microbial population or a  
61 consortia<sup>11</sup>. Recently, to probe the impact of antibiotics on energy metabolism at single-cell resolution, a  
62 genetically encoded FRET (Förster resonance energy transfer pair) of cyan and yellow fluorescent  
63 proteins flanking the epsilon subunit of the *Bacillus subtilis* F<sub>0</sub>F<sub>1</sub> ATP synthase was genetically  
64 introduced into *Mycobacterium smegmatis* as a sensor of intracellular ATP level<sup>12</sup>. However, the  
65 prerequisite for genetic manipulation (i.e., introduction of the reporter gene) limits the types of cells  
66 applicable, and essentially precludes its application on non-model organisms, uncultivated microbes, *in*  
67 *situ* analysis or point-of-care diagnosis.

68 Single-cell Raman Microspectroscopy is a non-destructive and externally label-free approach that  
69 provides comprehensive intrinsic molecular profile based on the vibrational frequencies of characteristic  
70 chemical bonds in a cell. Single-cell Raman Spectra (SCRS) have been employed to monitor bacterial  
71 phenotypic changes, mostly of macromolecule contents inside cells, during antimicrobial treatment at

72 either the population or the single cell level<sup>13-15</sup>. Recently we proposed the ‘Ramanome’ concept, and  
73 showed that a combination of 31 specific Raman peaks (i.e., Raman Barcode of Cellular Stress-response  
74 or RBCS) from SCRS randomly sampled from a cellular population can discriminate drug response  
75 programs based on cytotoxicity mechanism<sup>15</sup>. However, the multivariate nature of Ramanome, as well  
76 as its sensitivity to each of genetic background, physiological state and environment changes, can  
77 confound quantitative modeling and cross-species comparison of drug response.

78 In the presence of heavy water D<sub>2</sub>O, electron carriers NADPH and NADH, which are associated  
79 with cell general metabolic activity, can exchange H<sup>+</sup> in NADPH+H<sup>+</sup> with D<sup>+</sup> from D<sub>2</sub>O, and  
80 incorporate D<sup>+</sup> to form C-D bonds<sup>16-17</sup>. In D<sub>2</sub>O based Single-cell Raman microscopy (D<sub>2</sub>O-Raman), the  
81 rate of deuterium uptake in individual live cells via NADPH/NADH can be modeled by tracking the  
82 temporal shifting of C-H band to C-D band in a SCRS, due to the graduate substitution of C-H by the C-  
83 D bonds in intracellular macromolecules such as lipids and carbohydrates<sup>16-19</sup>. As intake of H<sub>2</sub>O or D<sub>2</sub>O  
84 is a universal and basic property of living cells, we hypothesize that D<sub>2</sub>O-Raman can serve as a non-  
85 invasive, quantitative and universal method to detect and measure metabolic activity of cells in response  
86 to drug treatments. "Minimum Inhibitory Concentration based on Metabolic Activity" (MIC-MA) was  
87 proposed to evaluate metabolism-inhibiting efficacy of drugs. In addition, Heterogeneity Index of MIC-  
88 MA (MIC-MA-HI), defined as Standard Deviation (SD) in C-D ratios of individual cells, was employed  
89 to quantitatively assess the heterogeneity of cellular metabolic activity in an isogenic population  
90 responding to drug regimens. We further showed that the method is able to detect the NGMA cells.  
91 Moreover, D<sub>2</sub>O-Raman can rapidly discriminate between antibiotic susceptible and resistant *S. mutans*  
92 strains. Thus D<sub>2</sub>O-Raman represents a universal method for rapid and quantitative assessment of  
93 antimicrobial effects based on metabolic activity at the single-cell level.

## 94 95 **Experimental methods**

### 96 **Microorganisms and growth conditions**

97 Five oral bacteria were tested in this study: (1) *Streptococcus mutans* UA159, (2) the fluoride-  
98 resistant *Streptococcus mutans* C180-2FR<sup>20</sup>, (3) *Streptococcus gordonii* ATCC10558, (4) *Streptococcus*  
99 *sanguinis* ATCC10556, and (5) *Lactobacillus fermentum* ATCC9338. Details of growth conditions,  
100 D<sub>2</sub>O exposure and drug administration are provided in **Supporting Information**.

### 101 **Acquisition and analysis of Single-cell Raman spectrum**

102 Cell pretreatment and SCRS acquisition were performed using a modified Raman spectrometer as  
103 described previously<sup>15, 17</sup>. All SCRS were processed by background subtraction (background defined as

1 104 the spectra of cell-free regions on the same slide), baseline correction and normalization using the  
2 105 Labspec5 software (Horiba Jobin Yvon Ltd, UK). The band intensity was normalized against (i) the  
3  
4 106 total area of the Raman spectrum or (ii) intensity of the tallest band in the Raman spectrum. The latter  
5  
6 107 was chosen in this work as the two normalization methods yield identical values of the ‘C-D ratio’. The  
7  
8 108 C-D ratio was defined as percentage of the integrated spectral intensity of the C-D band (2,040-2,300  
9 109  $\text{cm}^{-1}$ ) as compared to the sum of the C-D band and the predominant C-H band (2,800-3,100  $\text{cm}^{-1}$ ), so as  
10  
11 110 to quantify the degree of D substitution in C-H bonds. Standard deviation (SD) of the C-D ratio of  
12  
13 111 individual cells was used to quantify the degree of heterogeneity in D substitution. Chemometrics  
14  
15 112 analyses were performed using R (version 3.3.1) via customized scripts. Additional details are provided  
16 113 in **Supporting Information**.  
17

## 18 19 114 20 21 115 **Results and Discussion**

### 22 23 116 **Tracking deuterium incorporation in oral bacteria via Single-Cell Raman Spectra**

24  
25  
26 117 Oral microbiota play key roles in not only oral infections but also systemic diseases<sup>21-24</sup>. Here  
27  
28 118 employing four prevalent members of oral microbiota that include the Gram-positive *Streptococcus*  
29 119 *mutans* (strain UA159), *Streptococcus gordonii* (strain ATCC10558), *Streptococcus sanguinis* (strain  
30  
31 120 ATCC10556) and the Gram-negative *Lactobacillus fermentum* (strain ATCC9338), we tested the  
32  
33 121 general applicability of the D<sub>2</sub>O-Raman method in assessing bacterial metabolic activity. We started by  
34  
35 122 probing the sensitivity of bacterial growth to the D<sub>2</sub>O level in the medium. Compared with the control  
36 123 (i.e., D<sub>2</sub>O-free conditions) and as measured by OD<sub>600</sub> (**Supporting Information**), D<sub>2</sub>O of  $\leq 40\%$  in the  
37  
38 124 medium did not have significant inhibition on growth of *S. mutans* UA159 and *S. sanguinis*  
39  
40 125 ATCC10556 (**Fig. S1**), whereas *S. gordonii* ATCC10558 was more sensitive to D<sub>2</sub>O. Interestingly,  
41  
42 126 among these four model strains, *L. fermentum* ATCC9338 was able to tolerate high levels of D<sub>2</sub>O (up to  
43 127 50%) (**Fig. S1**).  
44

45  
46 128 For each of the bacteria and at each of the D<sub>2</sub>O levels tested, a broad C-D Raman band in 2,040 to  
47  
48 129 2,300  $\text{cm}^{-1}$  region emerged in SCRS, which was caused by a Raman shift of the original C-H peak  
49 130 (between 2,800 and 3,100  $\text{cm}^{-1}$ )<sup>16</sup> and intensity of the C-D band is proportional to D<sub>2</sub>O level in the  
50  
51 131 medium (**Fig. S2**), suggesting that all of these four bacteria actively take in D<sub>2</sub>O. No visible C-D peak  
52  
53 132 was observed in D<sub>2</sub>O-free cultures and the 2,040 to 2,300  $\text{cm}^{-1}$  region was flat as a ‘silent zone’ (**Fig.**  
54  
55 133 **S2**). Moreover, emergence of the C-D peak was rapid and does not require cell replication: e.g., in *S.*  
56 134 *mutans* (doubling time of  $60 \pm 5.5 \text{ min}^{25}$ ), the C-D band was detected at as early as 30 mins under 30%  
57  
58 135 D<sub>2</sub>O (**Fig. S3A**). In fact, temporal dynamics of the C-D band were different from the bacterial OD based  
59  
60

1 136 growth curve (**Fig. S3B**), since the C-D band appeared almost instantaneously after addition of D<sub>2</sub>O and  
2 137 reached the ‘logarithmic’ phase ~3 h earlier than the growth curve.  
3

4 138 On the other hand, temporal increase of the C-D ratio eventually reached a plateau during the first  
5  
6 139 8 h for *S. mutans* (**Fig. S3B**). Such “maximal C-D ratios” (defined as the C-D ratio at the plateau in the  
7  
8 140 absence of drugs) were linearly correlated with D<sub>2</sub>O level in the medium, although their slopes varied  
9  
10 141 (with *S. sanguinis* being the highest and *L. fermentum* the lowest; **Fig. 1**). Under 30% D<sub>2</sub>O, for each of  
11 142 the bacteria tested, the dynamic range of the C-D band was significant to allow quantification of its  
12  
13 143 intensity change, while bacterial growth remained unaffected (largely equivalent to that under  
14  
15 144 deuterium-free medium), hence 30% D<sub>2</sub>O was chosen as the default level in the medium for modeling  
16  
17 145 single-cell metabolic rates under various types, doses and exposure durations of drugs.  
18

### 19 146 **Kinetics of the C-D ratio quantitatively models metabolic inhibition of *S. mutans* UA159 by three** 20 21 147 **antimicrobials** 22

23 148 *S. mutans* UA159 is a clinical cariogenic strain that converts dietary carbohydrates to acids which  
24  
25 149 can eventually result in tooth demineralization<sup>26</sup>. To model its drug sensitivity, two antiseptics (NaF and  
26  
27 150 CHX) and one antibiotic (ampicillin), which are active ingredients in the mouthwash and frequently  
28  
29 151 used antibiotics for treating oral infections respectively, were chosen as models here to test the cellular  
30 152 response to drugs. Traditional methods for drug efficacy evaluation are mostly based on MIC, defined  
31  
32 153 as the minimal dose under which no visible bacterial growth (e.g., as measured by OD<sub>600</sub>) was detected  
33  
34 154 over 24 h of drug exposure (**Supporting Information**). The MICs of NaF, CHX and ampicillin for *S.*  
35  
36 155 *mutans* UA159 and that of NaF for *S. mutans* C180-2FR were first measured via OD<sub>600</sub>-based growth  
37 156 inhibition (**Table S1**). Then D<sub>2</sub>O-Raman based *S. mutans* UA159 responses were examined under  
38  
39 157 various doses for each drug. Temporal dynamics of the C-D ratio under NaF (**Fig. 2A**), CHX (**Fig. 2B**)  
40  
41 158 and ampicillin (**Fig. 2C**) treatment for up to 8 h shared several features. (i) These curves consist of a  
42  
43 159 ‘lag’ phase (e.g., under >MIC levels of NaF or CHX; the corresponding C-D ratio was termed as the  
44  
45 160 ‘baseline C-D ratio’), followed by a ‘logarithmic’ phase and then eventually a ‘saturated’ phase (the  
46 161 corresponding C-D ratio was termed as the ‘saturated C-D ratio’ for that particular dose). In the absence  
47  
48 162 of drugs, only the latter two phases were present and the saturated C-D ratio became the ‘maximal C-D  
49  
50 163 ratio’, which is a characteristic value to a given type of cells. (ii) Cells were highly sensitive to drug  
51  
52 164 doses, as increasing drug doses led to extension of the ‘lag’ phase, lower level of ‘logarithmic’ phase  
53 165 and reduced ‘saturated C-D ratio’. In fact, the slope at the logarithmic phase reduced in response to  
54  
55 166 increased drug doses, suggesting stronger inhibition of metabolic activity by higher drug doses. (iii) For  
56  
57 167 each of the drugs, cellular response was rapidly detected by the C-D ratio even under the lowest doses;  
58  
59 168 for example, under 0.2 g/L NaF (0.5× MIC) or 1.2 mg/L CHX (0.6× MIC), the difference to the drug-  
60

1 169 free control can be detected as early as 0.5 h ( $p < 0.01$ , Wilcoxon rank sum test; **Table S2**), suggesting  
2 170 high sensitivity of D<sub>2</sub>O-Raman in detecting drug effect.

3  
4 171 The time-course of the C-D ratio exhibited reproducible and highly distinct dose-dependency to  
5 the three drugs. For NaF (**Fig. 2A**), at 0.5× MIC (0.2 g/L), increase of the C-D ratio was initially lower  
6 172 than the drug-free control but reached nearly the same level as the control at 8 h. At the MIC dose of  
7 NaF (0.4 g/L), a ‘lag’ phase lasted 2 h, followed by a 4 h-long ‘logarithmic’ phase and then a ‘saturated’  
8 173 phase with ~40% of the maximal C-D ratio. At doses 1.5× or 3× MIC (i.e., 0.6 g/L or 1.2 g/L) of NaF,  
9 the C-D ratio remained at the baseline level from the start, indicating a complete inhibition of  
10 174 metabolism under these two doses. For CHX (**Fig. 2B**), at 0.6× MIC (1.2 mg/L), increase of the C-D  
11 175 ratio was also greatly delayed and at 8 h reached the plateau at 84% of the maximal C-D ratio. Under  
12 MIC (2 mg/L), the C-D ratio increased in the first 2~3 h and then plateaued at only 35% of the  
13 176 ‘maximal C-D ratio’ at 8h, suggesting 65% reduced yet still active cellular metabolism. At 2× MIC (4  
14 mg/L), the C-D ratio remained at the ‘baseline C-D ratio’ for the whole 8 h period, indicating  
15 completely inhibited cellular metabolism during the entire duration of CHX exposure.

16  
17 183 In contrast, when cells were exposed to ampicillin in the range of 0 to the exceedingly high >60×  
18 MIC (50 mg/L), no ‘lag’ phases were present, and in each case, the C-D ratio rapidly reached ‘saturated’  
19 184 phase (i.e., all before 3 h) at a very high ‘saturated C-D ratio’ (**Fig. 2C**). For example, after MIC-dose  
20 185 (0.8 mg/L) exposure for 8 h, a saturated C-D ratio was as high as 83% of the maximal C-D ratio. At the  
21 extreme high dose of >60× MIC (50 mg/L), the ‘saturated C-D ratio’ still remained 51% that of the  
22 186 maximal C-D ratio, indicating the presence of rather strong cellular metabolic activity after such  
23 treatments although cell growth was completely inhibited under 1× MIC (0.8 mg/L) of ampicillin  
24 187 (**Table S1**). This is drastically different to the dose response of NaF or CHX, as exposure to 2~3× MIC  
25 of NaF or CHX for just 30 min would have already brought the bacteria to the baseline of C-D ratio.  
26 188 Thus we hypothesized that under high dose of ampicillin, a large fraction of *S. mutans* cells would enter  
27 the NGMA state, where cells, despite not replicating, remain alive and retain a high level of metabolic  
28 189 activity.

29  
30 194 To test this hypothesis, *S. mutans* UA159 were exposed to 50 mg/L ampicillin (~60× MIC), 1.2  
31 g/L NaF (3× MIC) or 4 mg/L CHX (2× MIC) for 1.5 h in D<sub>2</sub>O-free BHI first, centrifuged to remove  
32 residual medium and then transferred to fresh BHI supplemented with identical type and dose of the  
33 197 pretreated drug and 30% D<sub>2</sub>O. The immediate detection by Single-cell Raman Microscopy revealed that  
34 the C-D ratio of SCRS from cells exposed to ampicillin increased within 1 h, while those exposed to  
35 198 NaF or CHX remained at the baseline C-D ratio (**Fig. S4**). To measure the degree of residual metabolic  
36 activity and thus quantitatively compare drug efficacy,  $\Delta$ C-D-ratio was defined as difference of the C-D  
37 199 ratio.

ratio of individual cells between a time point and the average C-D ratio of cells at 0 h (i.e., the ‘baseline C-D ratio’) under a particular dose for a given drug. At 1 h,  $\Delta$ C-D-ratio for ampicillin reached  $0.0078 \pm 0.0007$ , much higher than the background values for NaF ( $0.0009 \pm 0.0007$ ) and CHX ( $0.0002 \pm 0.0006$ ; **Fig. S4**). Thus metabolic activity of the cells remained high after the pre-exposure to  $>60 \times$  MIC of ampicillin for 1.5 h, despite being fully inhibited by  $3 \times$  MIC of NaF or  $2 \times$  MIC of CHX in the same period, suggesting that a large fraction of *S. mutans* cells has entered the NGMA state specifically under  $60 \times$  MIC of ampicillin.

To examine whether the treatment under high doses of the three drugs caused cell death or simply suppression of metabolic activity, *S. mutans* UA159 culture was sampled at various durations of drug exposure, washed to remove drug residuals and plated onto drug-free BHI agar. The Colony Forming Unit (CFU) was then measured to assess the post-drug-treatment cell viability. For NaF and CHX, the time-course pattern of CFU count was in agreement with that of the ‘saturated C-D ratio’, in that higher drug doses resulted in both lower CFU and lower ‘saturated C-D ratio’ (**Fig. 3**). However, for ampicillin, there was no such correlation between drug dose and CFU; moreover, even under  $60 \times$  MIC, 8 h of ampicillin exposure did not eradicate all bacteria ( $1.96 \times 10^7$  CFU/mL, versus  $6.90 \times 10^6$  CFU/mL for  $3 \times$  MIC NaF and  $7.70 \times 10^5$  CFU/mL for  $2 \times$  MIC CHX respectively; **Fig. 3 inset**) but the CFU was lower than that for the control at 8 h ( $7.07 \times 10^8$  CFU/mL). Thus all three drugs are bactericidal, although the killing effect of ampicillin is much weaker than NaF or CHX.

Intracellular ATP level of a cell population can be an indicator of the efficacy of antimicrobial agents, as its fluctuation is a secondary effect of drug response<sup>27</sup>. Thus to further validate our C-D ratio based method, the results were further compared to the intracellular ATP level of cell populations under drug treatment (**Methods**). For *S. mutans* UA159 cultures, under a series of NaF or CHX doses, similar dynamic patterns were observed between the intracellular ATP content (**Fig. 4A, 4B**) and the C-D ratio (**Fig. 2A, 2B**). Basically, increase in drug doses resulted in the decrease of intracellular ATP content, similar to that for the C-D ratio. For *S. mutans* UA159 cultures under ampicillin, the dose response of the intracellular ATP content were different, and there was no correlation between the intracellular ATP content and ampicillin dose (**Fig. 4C**). Moreover, even under very high ampicillin doses such as  $\sim 60 \times$  MIC (50 mg/L), no significant reduction of ATP homeostasis was observed for the bacterial population (**Fig. 4C**).

These observations can be potentially explained by the distinct antimicrobial action modes of the three drugs. CHX and NaF are both antiseptics: NaF inhibits cellular enolase and membrane ATPases<sup>28</sup>, while CHX disturbs the arrangement and integrity of the phospholipid bilayer of cells and causes inhibition of both membrane-bound and soluble ATPases<sup>29</sup>, thus both drugs resulted in reduced ATP

1 235 yield<sup>28-29</sup>. On the other hand, ampicillin, a  $\beta$ -lactam antibiotic, irreversibly inhibits the transpeptidase  
2 236 required for cell wall synthesis during binary fission<sup>30-32</sup> and does not directly inhibit ATP homeostasis,  
3  
4 237 and cells become longer without proper division<sup>15</sup>. This may explain the intracellular ATP content and  
5  
6 238 the emergence of NGMA *S. mutans* cells after ampicillin treatment. Moreover, bactericidal antibiotics  
7  
8 239 like ampicillin was thought to be of 'biphasic killing', in that an initial, rapid drop in bacterial counts  
9  
10 240 represents the death of the majority, while a subsequent, much slower phase of action exerts poor killing  
11241 effect of NGMA or persistence cells<sup>33</sup>, which are consistent with the cell viability test here.  
12

### 13242 **MIC-MA proposed for metabolic activity-based assessment of antimicrobial efficacy**

  
14

15  
16243 To quantitatively model antimicrobial effects, the  $\Delta$ C-D-ratio in SCRS at 8 h was chosen as the  
17244 default parameter for assessing drug effect, as after 8 h of drug treatment the C-D ratio already  
18  
19245 plateaued and was essentially identical to that after 24 h-exposure (**Fig. S5**). Moreover, the area where  
20  
21246  $\Delta$ C-D-ratio is below zero (i.e., with no metabolic activity detected) was designated as 'metabolism  
22  
23247 quiescence zone' (**Fig. 5**). For NaF (**Fig. 5A**), CHX (**Fig. 5B**) and ampicillin (**Fig. 5C**), the averaged  
24248  $\Delta$ C-D-ratios at 8 h were inversely proportional to the dose, despite a high degree of heterogeneity in  
25  
26249  $\Delta$ C-D-ratio among cells at each of the doses. Notably, for NaF and CHX, majority of the cells have  
27  
28250 entered the 'metabolism quiescence zone' under 2~3 $\times$  MIC (1.2 g/L of NaF and 4 mg/L of CHX),  
29  
30251 which is different from ampicillin where none of the cells sampled entered the zone even under 60 $\times$   
31252 MIC (50 mg/L).  
32  
33

34253 Thus to quantify antibacterial efficacy via metabolism inhibition instead of growth suppression,  
35  
36254 "Minimum Inhibitory Concentration based on Metabolic Activity" (MIC-MA) was proposed, which was  
37255 defined as the minimal dose under which the median value of  $\Delta$ C-D-ratio at 8 h of drug exposure is  $\leq 0$   
38  
39256 and the SD among the individual cells is  $\leq 0.005$ . For *S. mutans* UA159, the MIC-MA of NaF and CHX  
40  
41257 was 1.2 g/L (300% of MIC) and 4 mg/L (200% of MIC) respectively (**Table 1**). However, no MIC-MA  
42  
43258 was found for ampicillin, as *S. mutans* UA159 is able to maintain a high level of metabolism even under  
44259 60 $\times$  MIC of ampicillin (50 mg/L; **Fig. 5C**). For all the three drugs, MIC-MAs are higher than MIC  
45  
46260 (**Table 1**), which is expected as suppression of bacterial growth does not necessarily lead to inhibition  
47  
48261 of metabolic activity.  
49

50262 Moreover, a second parameter called Heterogeneity Index of MIC-MA (MIC-MA-HI), defined as  
51  
52263 Standard Deviation (SD) in C-D ratios of individual cells sampled from a given population, was  
53  
54264 proposed to quantitatively assess and track the heterogeneity of microbial metabolic activity under a  
55  
56265 particular time, dose and type of drug within a population; such heterogeneity in drug sensitivity is  
57266 crucial in development of drug resistance<sup>34</sup> and thus should be of great value to evaluation of drug  
58  
59267 efficacy. For each of the three drugs and at every dose tested, the MIC-MA-HI was significant, ranging  
60

1 268 from 0.002 at 1.2 g/L NaF and 0.011 at 1.2 mg/L CHX (**Fig. 5A, 5B**), underscoring the universality of  
2 269 microbial heterogeneity in drug response. For both NaF (**Fig. S6A**) and CHX (**Fig. S6B**), MIC-MA-HI  
3 was inversely proportional to drug dose. Higher doses generally resulted in lower heterogeneity along  
4 270 the 8 h of drug exposure, indicating that strong inhibition reduces heterogeneity of the metabolic activity  
5 271 across the population. Interestingly, for ampicillin (**Fig. S6C**), no inverse proportional correlation was  
6 272 observed ( $p > 0.05$ , Kruskal-Wallis test). Clearly, information such as MIC-MA-HI can be of vital value  
7 273 in decision making for the recommended drug, dosage and duration of exposure, since after drug  
8 274 treatment a bacterial population or consortium that exhibits low average metabolic activity yet harbors a  
9 275 subpopulation with robust metabolism can lead to chronic or reoccurring infections<sup>12</sup>.  
10  
11 276

12  
13 277 The heterogeneity of metabolic activity at single cell resolution can also be measured by  
14 278 introducing into the cell a sensor (coupled to fluorescence) of intracellular ATP level<sup>12</sup>; however the  
15 279 prerequisite for genetic manipulation limits the application of such approaches to laboratory model  
16 280 organisms. In contrast, due to its label-free nature, the D<sub>2</sub>O-Raman method may be generally applicable  
17 281 to most or all types of cells, and thus should be of particular value to non-model organisms, uncultivated  
18 282 microbes, *in situ* analysis and point-of-care diagnosis, where genetic transformation is typically not  
19 283 feasible or not readily available.  
20  
21

### 22 284 **The D<sub>2</sub>O-Raman Method distinguishes between drug susceptible and resistant *S. mutans***

23  
24 285 Fluoride is a widely used anti-caries ingredient in drinking water, toothpaste and mouthwash<sup>35</sup>,  
25 286 however fluoride-resistant *S. mutans* have emerged, causing failure or flawed control of tooth decay by  
26 287 fluoride<sup>20</sup>. To test whether our method can rapidly distinguish drug resistant strains, dynamics of the C-  
27 288 D ratio from SCRS was compared between the fluoride-sensitive (*S. mutans* UA159) and fluoride-  
28 289 resistant (*S. mutans* C180-2FR) strains under various doses of NaF. In the absence of fluoride (**Fig. 6A**),  
29 290 C-D ratios of the fluoride-resistant strain were lower than those of the sensitive strain in the first 3 h of  
30 291 inoculation and then reached a similar level after 4 h. This can be explained by the longer doubling time  
31 292 of C180-2FR ( $74.5 \pm 13.2$  min)<sup>36</sup> than UA159 ( $60 \pm 5.5$  min)<sup>25</sup>. Under 0.4 g/L NaF (MIC for UA159),  
32 293 for the fluoride-sensitive strain the C-D ratio stayed in the 'lag' phase before 2 h and then increased  
33 294 rapidly thereafter. In contrast, for the fluoride-resistant strain, the temporal pattern of the C-D ratio was  
34 295 identical to that under NaF-free medium, suggesting that its metabolic activity was unaffected and the  
35 296 strain was insensitive to 0.4 g/L NaF (**Fig. 6B**). In fact, the C-D ratio is able to distinguish the two  
36 297 strains in as early as 0.5 h ( $p < 0.01$ , Wilcoxon rank sum test; **Table S3**). Under 1.6 g/L NaF (MIC for  
37 298 C180-2FR) for the resistant strain or under 1.2 g/L NaF ( $3 \times$  MIC for UA159) for the sensitive strain,  
38 299 although cell metabolism (as measured by the C-D ratio) were consistently weaker at each time point  
39 300 than under NaF-free and 0.4 g/L NaF conditions, the C-D ratio of fluoride-sensitive strain remained at  
40  
41

1 301 the baseline level throughout the 8 hrs, yet in contrast, that of the resistant strain started increasing  
2 302 rather rapidly after 1 h (**Fig. 6C**). Thus D<sub>2</sub>O-Raman is able to rapidly screen drug-resistant microbes.  
3  
4

## 5 303 6 7 304 **Conclusions**

8  
9  
10 305 The spread of drug resistance demands rapid, sensitive and reliable methods for quantitative  
11 306 assessment of antimicrobial activities<sup>1-2</sup>. Here we developed the D<sub>2</sub>O-Raman method as a growth-  
12  
13 307 independent approach for measurement of cellular metabolic activity in response to drug treatment at  
14  
15 308 the single-cell level. In addition, MIC-MA was proposed as a basis for quantitative assessment and  
16  
17 309 comparison of drug efficacy based on residual metabolic activity of the bacteria as well as the associated  
18  
19 310 intercellular heterogeneity quantified by MIC-MA-HI.

20  
21 311 The D<sub>2</sub>O-Raman method, which can be considered as one extreme case of the Ramanome  
22 312 approach<sup>15</sup>, has several advantages compared to other single-cell phenotyping methods. (i) It allowed  
23 313 measurement of metabolic activity of individual cells without prior knowledge of their physiology status  
24  
25  
26 314 or changing their biological context. (ii) D<sub>2</sub>O can be directly combined with any external stimuli to  
27  
28 315 probe their effects on target cells. (iii) D<sub>2</sub>O uptake is more sensitive and rapid than other stable isotopes  
29  
30 316 such as <sup>13</sup>C in inducing detectable change in SCRS<sup>17</sup>. (iv) In the presence of D<sub>2</sub>O, dead cells are unable  
31 317 to form C-D bands in SCRS, which can be readily distinguished from those NGMA cells. (v) Due to its  
32  
33 318 non-destructive manner, this method can be coupled to Raman-activated Cell Sorting and the  
34  
35 319 subsequent single-cell DNA/RNA sequencing<sup>37-42</sup>, thus linking bacterial genotypes to key phenotypes  
36  
37 320 such as those underlying antibiotic-resistant or dormant sub-populations in recurrent infections<sup>5,6</sup>. On  
38  
39 321 the other hand, the D<sub>2</sub>O-Raman method can be labor-intensive and of low throughput. As the Raman  
40 322 spectrum for each bacterial cell took 10 seconds to acquire and at least 20 cells were randomly selected  
41  
42 323 manually for imaging, currently it can take 5~10 mins for analyzing each cell population. Ongoing  
43  
44 324 software development in our laboratory that automates cell selection, SCRS acquisition and data  
45  
46 325 analysis should greatly improve the throughput of D<sub>2</sub>O-Raman experiments.

47  
48 326 Finally, although several oral bacteria were employed as models here, the D<sub>2</sub>O-Raman method is  
49  
50 327 generally applicable to a much wider range of cells. For example, a database of MIC-MA and MIC-MA-  
51 328 HI can be built to assess and compare metabolic-activity inhibitory effects of presently available  
52  
53 329 antibiotics on the frequently encountered pathogens and cosmopolitan microbes. This database is  
54  
55 330 complementary to the MIC-based one<sup>43</sup>, and can serve as a new guideline to physicians in  
56  
57 331 recommending the optimal type, dose and duration of antibiotics. As demonstrated in the case of  
58  
59 332 ampicillin here, MIC-MA based recommendations of treatment regimen can be very different from  
60

1 333 those derived from MIC, thus the MIC-MA derived guideline might be valuable not just for patient  
2 334 treatment but for the combat against spread of antibiotic resistance. Moreover, the D<sub>2</sub>O-Raman method  
3  
4 335 may form the basis of a new drug screening platform, as it can potentially measure drug effect on  
5  
6 336 metabolism of mammalian or human cells at single-cell resolution. Furthermore, the independence of  
7  
8 337 cell propagation is a highly desirable feature of the method that can be exploited for personalized drug  
9 338 sensitivity testing. In summary, the D<sub>2</sub>O-Raman method and the MIC-MA and MIC-MA-HI concepts  
10  
11 339 can serve as a generally applicable technological foundation for quantitative efficacy evaluation of  
12  
13 340 antimicrobials, selection of drug treatment regimens and personalized drug sensitivity assessment and  
14  
15 341 precision medicine.

## 19 343 Supporting Information

20  
21 344 Supporting Information Available: Method description of the microorganisms and growth conditions  
22  
23 345 used, Acquisition of Single-cell Raman Spectra, Tests for Minimal Inhibitory Concentration of selected  
24  
25 346 antimicrobial drugs, and Measurements of intracellular ATP content from bulk cells; Supplemental  
26  
27 347 tables for MIC measurements and statistical analysis; Supplemental figures for change of OD<sub>600</sub>, Single-  
28  
29 348 cell Raman spectra, C-D ratio or inter-cellular heterogeneity in metabolic activity with time or drug  
30  
31 349 dose. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## 35 351 Acknowledgements

36  
37  
38 352 J.X. acknowledges support of grants 91231205, 31327001 and 31425002 from NSFC and  
39  
40 353 XDB15040100 from CAS. Y.J. acknowledges support of 2015ZDJS04002 from Shandong Province.  
41 354 Y.W thanks financial support of 31400436 from NSFC. W.E.H thanks support from EPSRC  
42  
43 355 (EP/M002403/1) and NERC (NE/M002934/1) in the UK. S.H thanks support from NSFC (31400089)  
44  
45 356 and China Postdoctoral Science Foundation Grant (2016LH00036). The authors thank Mingming Sun  
46  
47 357 for the TOC artwork.

## 51 359 List of Abbreviations

53 54 360	CFU	Colony Forming Unit
55 56 361	CHX	chlorhexidine
57 58 362	MIC	Minimum Inhibitory Concentration

1	363	MIC-MA	Minimum Inhibitory Concentration based on Metabolic Activity
2	364	MIC-MA-HI	Heterogeneity Index of MIC-MA
3			
4	365	NaF	sodium fluoride
5			
6	366	NGMA	non-growing but metabolically active
7			
8	367	SCRS	Single-cell Raman Spectra
9			
10	368	SD	Standard Deviation
11			
12	369		
13			
14			
15	370		

## REFERENCES

1. Matthiessen, L.; Bergstrom, R.; Dustdar, S.; Meulien, P.; Draghia-Akli, R., *Lancet* **2016**, *388*, 865-865.
2. Laxminarayan, R.; Sridhar, D.; Blaser, M.; Wang, M. G.; Woolhouse, M., *Science* **2016**, *353*, 874-875.
3. Balouiri, M.; Sadiki, M.; Ibsouda, S. K., *J Pharm Anal* **2016**, *6*, 71-79.
4. Bergkessel, M.; Basta, D. W.; Newman, D. K., *Nat Rev Microbiol* **2016**, *14*, 549-562.
5. Harms, A.; Maisonneuve, E.; Gerdes, K., *Science* **2016**, *354*.
6. Manina, G.; Dhar, N.; McKinney, J. D., *Cell Host Microbe* **2015**, *17*, 32-46.
7. Paloque, L.; Vidal, N.; Casanova, M.; Dumetre, A.; Verhaeghe, P.; Parzy, D.; Azas, N., *J Microbiol Meth* **2013**, *95*, 320-323.
8. Andreu, N.; Fletcher, T.; Krishnan, N.; Wiles, S.; Robertson, B. D., *J Antimicrob Chemother* **2012**, *67*, 404-414.
9. Hara, K. Y.; Shimodate, N.; Ito, M.; Baba, T.; Mori, H.; Mori, H., *Metab Eng* **2009**, *11*, 1-7.
10. Lobritz, M. A.; Belenky, P.; Porter, C. B. M.; Gutierrez, A.; Yang, J. H.; Schwarz, E. G.; Dwyer, D. J.; Khalil, A. S.; Collins, J. J., *Proc Natl Acad Sci* **2015**, *112*, 8173-8180.
11. Eldar, A.; Elowitz, M. B., *Nature* **2010**, *467*, 167-73.
12. Maglica, Z.; Ozdemir, E.; McKinney, J. D., *mBio* **2015**, *6*, e02236-14.
13. Assmann, C.; Kirchoff, J.; Beleites, C.; Hey, J.; Kostudis, S.; Pfister, W.; Schlattmann, P.; Popp, J.; Neugebauer, U., *Anal Bioanal Chem* **2015**, *407*, 8343-52.
14. Schroder, U. C.; Beleites, C.; Assmann, C.; Glaser, U.; Hubner, U.; Pfister, W.; Fritzsche, W.; Popp, J.; Neugebauer, U., *Sci Rep-Uk* **2015**, *5*.
15. Teng, L.; Wang, X.; Wang, X.; Gou, H.; Ren, L.; Wang, T.; Wang, Y.; Ji, Y.; Huang, W. E.; Xu, J., *Sci Rep* **2016**, *6*, 34359.
16. Berry, D.; Mader, E.; Lee, T. K.; Wobken, D.; Wang, Y.; Zhu, D.; Palatinszky, M.; Schintmeister, A.; Schmid, M. C.; Hanson, B. T.; Shterzer, N.; Mizrahi, I.; Rauch, I.; Decker, T.; Bocklitz, T.; Popp, J.; Gibson, C. M.; Fowler, P. W.; Huang, W. E.; Wagner, M., *Proc Natl Acad Sci* **2015**, *112*, E194-E203.
17. Wang, Y.; Song, Y.; Tao, Y.; Muhamadali, H.; Goodacre, R.; Zhou, N. Y.; Preston, G. M.; Xu, J.; Huang, W. E., *Anal Chem* **2016**, *88*, 9443-9450.
18. Kumar, B. N. V.; Guo, S.; Bocklitz, T.; Rosch, P.; Popp, J., *Anal Chem* **2016**, *88*, 7574-82.
19. Eichorst, S. A.; Strasser, F.; Woyke, T.; Schintmeister, A.; Wagner, M.; Wobken, D., *FEMS Microbiol Ecol* **2015**, *91*.
20. Van Loveren, C.; Spitz, L. M.; Buijs, J. F.; Ten Cate, J. M.; Eisenberg, A. D., *J Dent Res* **1991**, *70*, 1491-6.
21. Gross, E. L.; Leys, E. J.; Gasparovich, S. R.; Firestone, N. D.; Schwartzbaum, J. A.; Janies, D. A.; Asnani, K.; Griffen, A. L., *J Clin Microbiol* **2010**, *48*, 4121-4128.

- 407 22. Kostic, A. D.; Chun, E. Y.; Robertson, L.; Glickman, J. N.; Gallini, C. A.; Michaud, M.; Clancy,  
1 408 T. E.; Chung, D. C.; Lochhead, P.; Hold, G. L.; El-Omar, E. M.; Brenner, D.; Fuchs, C. S.; Meyerson,  
2 409 M.; Garrett, W. S., *Cell Host Microbe* **2013**, *14*, 207-215.
- 3 410 23. Rubinstein, M. R.; Wang, X. W.; Liu, W. D.; Hao, Y. J.; Cai, G. F.; Han, Y. P. W., *Cell Host*  
4 411 *Microbe* **2013**, *14*, 195-206.
- 5 412 24. Gao, S. G.; Li, S. G.; Ma, Z. K.; Liang, S.; Shan, T. Y.; Zhang, M. X.; Zhu, X. J.; Zhang, P. F.;  
6 413 Liu, G.; Zhou, F. Y.; Yuan, X.; Jia, R. N.; Potempa, J.; Scott, D. A.; Lamont, R. J.; Wang, H. Z.; Feng,  
7 414 X. S., *Infect Agents Cancer* **2016**, *11*.
- 8 415 25. Abranches, J.; Lemos, J. A.; Burne, R. A., *Fems Microbiol Lett* **2006**, *255*, 240-6.
- 9 416 26. Loesche, W. J., *Microbiol Rev* **1986**, *50*, 353-380.
- 10 417 27. Mak, P. A.; Rao, S. P. S.; Tan, M. P.; Lin, X. H.; Chyba, J.; Tay, J.; Ng, S. H.; Tan, B. H.;  
11 418 Cherian, J.; Duraiswamy, J.; Bifani, P.; Lim, V.; Lee, B. H.; Ma, N. L.; Beer, D.; Thayalan, P.; Kuhen,  
12 419 K.; Chatterjee, A.; Supek, F.; Glynne, R.; Zheng, J.; Boshoff, H. I.; Barry, C. E.; Dick, T.; Pethe, K.;  
13 420 Camacho, L. R., *ACS Chem Biol* **2012**, *7*, 1190-1197.
- 14 421 28. Sutton, S. V. W.; Bender, G. R.; Marquis, R. E., *Infect Immun* **1987**, *55*, 2597-2603.
- 15 422 29. Cheung, H. Y.; Wong, M. M. K.; Cheung, S. H.; Liang, L. Y.; Lam, Y. W.; Chiu, S. K., *PLoS*  
16 423 *One* **2012**, *7*.
- 17 424 30. Wise, E. M.; Park, J. T., *Proc Natl Acad Sci* **1965**, *54*, 75-&.
- 18 425 31. Tipper, D. J.; Strominger, J. L., *Proc Natl Acad Sci* **1965**, *54*, 1133-1141.
- 19 426 32. Moore, B. A.; Jevons, S.; Brammer, K. W., *Antimicrob Agents Chemother* **1979**, *15*, 831-833.
- 20 427 33. Balaban, N. Q.; Merrin, J.; Chait, R.; Kowalik, L.; Leibler, S., *Science* **2004**, *305*, 1622-1625.
- 21 428 34. Sanchez-Romero, M. A.; Casadesus, J., *Proc Natl Acad Sci U S A* **2014**, *111*, 355-60.
- 22 429 35. Bowen, W. H., *J R Soc Med* **1995**, *88*, 505-7.
- 23 430 36. Liao, Y.; Chen, J.; Brandt, B. W.; Zhu, Y.; Li, J.; van Loveren, C.; Deng, D. M., *PLoS One*  
24 431 **2015**, *10*, e0122630.
- 25 432 37. Wang, Y.; Ji, Y. T.; Wharfe, E. S.; Meadows, R. S.; March, P.; Goodacre, R.; Xu, J.; Huang, W.  
26 433 E., *Anal Chem* **2013**, *85*, 10697-10701.
- 27 434 38. Ji, Y.; He, Y.; Cui, Y.; Wang, T.; Wang, Y.; Li, Y.; Huang, W. E.; Xu, J., *Biotechnol. J* **2014**, *9*,  
28 435 1512-8.
- 29 436 39. Zhang, P.; Ren, L.; Zhang, X.; Shan, Y.; Wang, Y.; Ji, Y.; Yin, H.; Huang, W. E.; Xu, J.; Ma,  
30 437 B., *Anal Chem* **2015**, *87*, 2282-9.
- 31 438 40. Zhang, Q.; Zhang, P.; Gou, H.; Mou, C.; Huang, W. E.; Yang, M.; Xu, J.; Ma, B., *The Analyst*  
32 439 **2015**, *140*, 6163-74.
- 33 440 41. Wang, T.; Ji, Y.; Wang, Y.; Jia, J.; Li, J.; Huang, S.; Han, D.; Hu, Q.; Huang, W. E.; Xu, J.,  
34 441 *Biotech Biofuels* **2014**, *7*, 58.
- 35 442 42. Song Y, Davison PA, Frentrup M, Preston GM, Thompson IP, Murrell JC, Yin H, et al., *Microb*  
36 443 *Biotechnol.* 201610, 125-137.
- 37 444 43. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial  
38 445 susceptibility testing; twenty-third informational supplement. CLSI document M100-S23CLSI, Wayne,  
39 446 PA, 2013.
- 40 447
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

448 **Table**449 **Table 1.** Comparison between MIC-MA and MIC of three antibacterials for *Streptococcus mutans*  
450 UA159.

451

	NaF (g/L)	CHX (mg/L)	Ampicillin (mg/L)
MIC	0.4	2	0.8
MIC-MA	1.2	4	>50

12452

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56


57

58


59

60


## Figures




**Figure 1. Correlation between the saturated C-D ratio and the D<sub>2</sub>O concentration for four oral bacterial species.** The bacteria were grown respectively under a series of D<sub>2</sub>O levels and then cultured for 12 hours (when each culture reached the stationary phase and the C-D ratio also reached saturation), followed by SCRS measurement. Each point represents the average C-D ratio of SCRS from 60 cells (20 from each of three biological replicates of culture), with error bar indicating standard deviation among the three biological replicates.




**Figure 2. Temporal dynamics of the C-D ratio of *S. mutans* UA159 under increasing doses of NaF (A), CHX (B) or ampicillin (C).** Each point represents the average C-D ratio of SCRS of 60 cells (20 from each of three biological replicates of culture), with error bar indicating standard deviation among the three biological replicates.




**Figure 3. Cell recovery probability after various duration of treatment under a series of drug doses.** Cells from cultures under drug treatments were collected at each time point, washed to remove residual medium, diluted with fresh BHI medium for a series of times, plated onto BHI agar and cultured at 37 °C for 36 h. Those plates with Colony forming units (CFUs) between 30 to 300 were counted. Value represents calculated CFU in 1 mL culture and error bar indicates standard error. For clear view of the cell recovery rates after drug treatment, CFU curves with drug-free controls masked were shown as insets.



**Figure 4. Temporal dynamics of the intracellular ATP level of bulk *S. mutans* UA159 cells under increasing doses of NaF (A), CHX (B) or ampicillin (C).** Cells were cultured in BHI broth under the drug doses in presence of 30% D<sub>2</sub>O. Results are presented by means ± SE ( $n = 3$ ).



**Figure 5. Dose effects of NaF (A), CHX (B) or ampicillin (C) on  $\Delta$ C-D-ratio of *S. mutans* UA159 cells.**  $\Delta$ C-D-ratio at 8 h was plotted over the various doses. The red line, which was generated via the 'Loess' regression<sup>43</sup>, represents the tendency of  $\Delta$ C-D-ratio variation among the increasing doses. Each dot represents a cell.



**Figure 6. Temporal dynamics of C-D ratio for the NaF-sensitive *S. mutans* UA159 and the NaF-resistant C180-2FR cells under various doses of NaF.** (A) NaF-free conditions on both strains. (B) 0.4 g/L NaF (MIC of UA159) for both strains. (C) 1.2 g/L NaF for UA159 and 1.6 g/L NaF (MIC of C180-2FR) for C180-2FR. Value represents the average C-D ratio of SCRS from 60 cells from three biological replicates, with error bar indicating standard error among 60 cells.

496 TOC: Measurement of MIC-MA using D<sub>2</sub>O-Raman.